Home › Compare › EGRAF vs JNJ

EGRAF vs JNJ: Dividend Comparison 2026

EGRAF yields 55865.92% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EGRAF wins by $1.4476931785670793e+24M in total portfolio value
10 years
EGRAF
EGRAF
● Live price
55865.92%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.4476931785670793e+24M
Annual income
$1,442,613,446,757,378,300,000,000,000,000.00
Full EGRAF calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — EGRAF vs JNJ

📍 EGRAF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEGRAFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EGRAF + JNJ cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
EGRAF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EGRAF
Annual income on $10K today (after 15% tax)
$4,748,603.35/yr
After 10yr DRIP, annual income (after tax)
$1,226,221,429,743,771,500,000,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, EGRAF beats the other by $1,226,221,429,743,771,500,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EGRAF + JNJ for your $10,000?

EGRAF: 50%JNJ: 50%
100% JNJ50/50100% EGRAF
Portfolio after 10yr
$7.238465892835397e+23M
Annual income
$721,306,723,378,689,100,000,000,000,000.00/yr
Blended yield
99.65%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

EGRAF
No analyst data
Altman Z
-3.7
Piotroski
4/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EGRAF buys
0
JNJ buys
0
No recent congressional trades found for EGRAF or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEGRAFJNJ
Forward yield55865.92% ✓3.36%
Annual dividend / share$2.00$4.96 ✓
Payout ratio50% ✓55%
1-year div growth0%4.2% ✓
5-year div CAGR0%5.8% ✓
Portfolio after 10y$1.4476931785670793e+24M$20.0K ✓
Annual income after 10y$1,442,613,446,757,378,300,000,000,000,000.00 ✓$827.78
Total dividends collected$1.4473598380245791e+24M$5.6K ✓
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: EGRAF vs JNJ ($10,000, DRIP)

YearEGRAF PortfolioEGRAF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$5,597,292$5,586,592.18$10,676$355.77+$5.59M → EGRAF
2$2,928,399,262$2,922,410,159.65$11,407$389.39+$2928.39M → EGRAF
3$1,432,059,268,507$1,428,925,881,296.16$12,198$426.53+$1432059.26M → EGRAF
4$654,597,633,285,438$653,065,329,868,136.10$13,056$467.62+$654597633.27M → EGRAF
5$279,688,911,228,007,870$278,988,491,760,392,480.00$13,987$513.12+$279688911227.99M → EGRAF
6$111,703,919,794,457,660,000$111,404,652,659,443,700,000.00$14,998$563.56+$111703919794457.64M → EGRAF
7$41,702,226,168,962,334,000,000$41,582,702,974,782,270,000,000.00$16,098$619.52+$41702226168962336.00M → EGRAF
8$14,553,029,528,779,633,000,000,000$14,508,408,146,778,844,000,000,000.00$17,295$681.69+$14553029528779632640.00M → EGRAF
9$4,747,412,906,262,608,000,000,000,000$4,731,841,164,666,813,500,000,000,000.00$18,599$750.82+$4.747412906262608e+21M → EGRAF
10$1,447,693,178,567,079,400,000,000,000,000$1,442,613,446,757,378,300,000,000,000,000.00$20,022$827.78+$1.4476931785670793e+24M → EGRAF

EGRAF vs JNJ: Complete Analysis 2026

EGRAF — Stock

Energy Resources of Australia Ltd operates as a uranium producer. It holds a 100% interest in the Jabiluka mineral lease. The company was incorporated in 1980 and is headquartered in Darwin, Australia. Energy Resources of Australia Ltd is a subsidiary of North Limited.

Full EGRAF Calculator →

JNJ — Healthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this EGRAF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EGRAF vs SCHDEGRAF vs JEPIEGRAF vs OEGRAF vs KOEGRAF vs MAINEGRAF vs ABBVEGRAF vs MRKEGRAF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.